These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 9462449)
1. Activity of cefepime against resistant strains of Pseudomonas aeruginosa. Talon D; Thouverez M; Mulin B J Antimicrob Chemother; 1997 Dec; 40(6):909-10. PubMed ID: 9462449 [No Abstract] [Full Text] [Related]
2. In vitro activity of ceftazidime, cefepime and imipenem on 1,005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams. Bonfiglio G; Marchetti F Chemotherapy; 2000; 46(4):229-34. PubMed ID: 10859428 [TBL] [Abstract][Full Text] [Related]
3. In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Christenson JC; Korgenski EK; Daly JA J Antimicrob Chemother; 2000 Jun; 45(6):899-901. PubMed ID: 10837448 [TBL] [Abstract][Full Text] [Related]
4. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa. Watanabe N; Hiruma R; Katsu K J Antimicrob Chemother; 1992 Nov; 30(5):633-41. PubMed ID: 1493980 [TBL] [Abstract][Full Text] [Related]
5. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. Erdem I; Kucukercan M; Ceran N Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429 [TBL] [Abstract][Full Text] [Related]
7. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates. Humphries RM; Hindler JA; Wong-Beringer A; Miller SA Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338 [TBL] [Abstract][Full Text] [Related]
8. [The effect of cefepime on ceftazidime, cefotaxime and imipenem resistant strains of Acinetobacter, Xanthomonas, Pseudomonas, Flavobacterium, Sphingobacterium and on producers of extended spectrum beta-lactamases (ESBL) with resistance transfer]. Blahová J; Hupková-Lesická M; Králiková K; Krcméry V; Kubonová K Cas Lek Cesk; 1997 Mar; 136(5):154-6. PubMed ID: 9221190 [TBL] [Abstract][Full Text] [Related]
9. Development of resistance to imipenem among nosocomial isolates of Pseudomonas aeruginosa. Başustaoğlu AC; Gün H; Saraçli MA; Baysallar M; Haznedaroğlu T Eur J Clin Microbiol Infect Dis; 1995 May; 14(5):469-70. PubMed ID: 7556242 [No Abstract] [Full Text] [Related]
10. Resistance to imipenem in Pseudomonas aeruginosa. King A; Shannon K; Phillips I J Antimicrob Chemother; 1995 Dec; 36(6):1037-41. PubMed ID: 8821603 [TBL] [Abstract][Full Text] [Related]
11. [Participation of metallo-beta-lactamases in resistance to imipenem and meropenem in clinical strains of Pseudomonas aeruginosa and Acinetobacter spp]. Sacha P; Wieczorek P; Jakoniuk P; Zórawski M Wiad Lek; 2008; 61(1-3):30-6. PubMed ID: 18717040 [TBL] [Abstract][Full Text] [Related]
12. Postantibiotic effect of carbapenems against Pseudomonas aeruginosa. Hikida M; Yamazaki Y; Yoshida M; Kawashima K; Nishiki K; Mitsuhashi S J Antibiot (Tokyo); 1995 Aug; 48(8):891-2. PubMed ID: 7592037 [No Abstract] [Full Text] [Related]
13. [A novel carbapenem active against imipenem resistant strains of Pseudomonas aeruginosa]. Sazykin YuO Antibiot Khimioter; 1997; 42(8):42. PubMed ID: 9412413 [No Abstract] [Full Text] [Related]
14. Effect of beta-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginosa. Carsenti-Etesse H; Cavallo JD; Roger PM; Ziha-Zarifi I; Plesiat P; Garrabe E; Dellamonica P Chirurgia (Bucur); 2002; 97(2):151-9. PubMed ID: 12731225 [TBL] [Abstract][Full Text] [Related]
15. [Study on antibiotics susceptibility and mechanism of carbapenem-resistance in clinical isolates of Pseudomonas aeruginosa]. Arita K; Daido K; Ohashi N; Nakamura K; Takeshima Y; Kohara T Jpn J Antibiot; 1999 Jul; 52(7):491-6. PubMed ID: 10516928 [TBL] [Abstract][Full Text] [Related]
16. [In vitro activity of six beta-lactams against 295 strains of enterobacteriaceae and P. aeruginosa isolated from neutropenic patients]. Maugein J; Perrier F; Cony Makhoul P; Fourche J; Darmaillac V Pathol Biol (Paris); 1995 Apr; 43(4):253-7. PubMed ID: 7567110 [TBL] [Abstract][Full Text] [Related]
17. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program. Turner PJ Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798 [TBL] [Abstract][Full Text] [Related]
18. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents. Goff DA; Nicolau DP Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574 [TBL] [Abstract][Full Text] [Related]
19. Transduction of imipenem resistance by wild-type bacteriophages carried by three strains of Pseudomonas aeruginosa isolated from a single source. Blahová J; Králiková K; Krcméry V; Mlynarcík D; Trupl J J Antimicrob Chemother; 1998 Jun; 41(6):660-2. PubMed ID: 9687107 [No Abstract] [Full Text] [Related]
20. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group. Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]